Business Context and Reporting Period
Company: CG Oncology, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 26, 2025
Reporting Period: Data cutoff for clinical trial results is March 14, 2025.
Context: The filing discloses updated clinical data for cretostimogene grenadenorepvec (cretostimogene) from the BOND-003 Phase 3 clinical trial, presented at the American Urological Association Annual Meeting.
Key Financial Metrics
This Form 8-K is a disclosure of clinical trial results and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Data
The filing reports significant clinical updates for the BOND-003 Phase 3 trial evaluating cretostimogene as monotherapy for high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC):
- Cohort C (Patients with CIS):
- Complete Response (CR) at any time: 75.5%.
- Confirmed CRs at 24 months: 34 patients (9 pending assessment).
- CR rates by Kaplan-Meier estimation: 50.7% at 12 months and 42.3% at 24 months.
- Median Duration of Response (DOR): 28 months (ongoing).
- Progression-free rate: 97.3% of patients were free from progression to muscle invasive disease at 24 months.
- Treatment adherence: 97.3% of patients completed all expected treatments.
- Cohort P (Patients with Ta/T1 disease without CIS):
- High-grade recurrence-free survival: Estimated 90.5% (95% CI: 77.9, 100.0) at 3 and 9 months in 24 treated patients.
- Safety Profile:
- No Grade 3 or greater treatment-related adverse events (TRAEs) or deaths reported.
- Median resolution time for TRAEs: One day.
- No treatment-related discontinuations observed.
- Most common TRAEs (≥10%): Bladder spasm, pollakiuria, micturition urgency, dysuria, and hematuria.
Guidance, Outlook, and Risks
Management Commentary: The Company characterizes the data as demonstrating "best-in-disease durability" and a "promising early signal" in Cohort P. The safety profile is described as generally well-tolerated.
Forward-Looking Statements: The filing includes standard disclaimers regarding potential therapeutic benefits, durability, and advantages over existing therapies. Actual results may differ due to risks including inconsistent future data, unexpected adverse side effects, inadequate efficacy, trial delays, and competitive developments.
Contingencies: The Company notes it does not intend to file a Form 8-K for every update to its corporate presentation, which was updated on April 28, 2025.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed statistical tables.
- Review the updated corporate presentation on the Company's website (www.cgoncology.com) for additional context.
- Confirm the definition of "complete response" and "high-grade recurrence-free survival" in the context of the BOND-003 trial protocol.
- Monitor future filings for the final analysis of the 9 patients in Cohort C pending their 24-month assessment.
- Assess the impact of the 97.3% progression-free rate on potential regulatory approval timelines for cretostimogene.